Treating Generalized Pustular Psoriasis (GPP): Timing and Rationale for Biologic Treatment Switching—A Japanese e-Delphi Survey
Switches may occur for patients on biologics when flares occur (loss of effectiveness) or when there is insufficient response (lack of effectiveness). The decision to switch a biologic is impacted by several other criteria, including safety and the availability of more efficacious and better tolerated therapies. Overall, there is still an unmet need for robust evidence to inform GPP treatment choice.
Authors
- T Mitsuma
- Shinichi Imafuku
- Ayumi Yoshizaki (ORCID: https://orcid.org/0000-0002-8194-9140)
- Noriko Tsuruta (ORCID: https://orcid.org/0000-0002-2907-9205)
- Masatoshi Abe (ORCID: https://orcid.org/0000-0002-8863-9428)
- Yayoi Tada (ORCID: https://orcid.org/0000-0003-3743-135X)
- Kazumitsu Sugiura (ORCID: https://orcid.org/0000-0002-5207-4592)
- Yukie Yamaguchi (ORCID: https://orcid.org/0000-0002-0297-6627)
- Akimichi Morita (ORCID: https://orcid.org/0000-0001-8372-3754)
- Hideki Fujita
Institutions
- Nihon University (JP)
- Nagoya City University (JP)
- Fukuoka University Hospital (JP)
- Yokohama City University Hospital (JP)
- Ichinomiya Municipal City Hospital (JP)
- Fujita Health University Hospital (JP)
- Kitakyushu City Hospital Organization (JP)
- The University of Tokyo (JP)
- Teikyo University (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1007/s13555-025-01377-3
- Citations
- 2
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 1.59